Huadong Medicine (000963.SZ): The application for marketing approval of Remifentanil injection has been approved.
East China Medicine (000963.SZ) announced that its wholly-owned subsidiary Hangzhou Sino-America East China Pharmaceutical Co., Ltd. (referred to as "...
Huadong Medicine (000963.SZ) announces that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong") has received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA). The application for the market approval of Remabizine Injection submitted by Zhongmei Huadong has been approved. This drug is an injectable exogenous fluorescent tracer, which needs to be used in conjunction with the transdermal glomerular filtration rate measuring device (TGFR) produced by MediBeacon Inc to evaluate the glomerular filtration rate (GFR) of patients.
Related Articles
US Stock Market Move | ACCL.US, a company controlled by Zhuo Yuan, has landed on the US stock market with a 1.75% increase in trading at the opening.
US Stock Market Move | NVIDIA Corporation holds Concept Stock Coreweave (CRWV.US), which fell more than 7%.
US Stock Market Move | Reach a $1.085 billion cooperation agreement with domestic and foreign pharmaceutical companies, Rani Therapeutics (RANI.US) soars over 265%.
US Stock Market Move | ACCL.US, a company controlled by Zhuo Yuan, has landed on the US stock market with a 1.75% increase in trading at the opening.
US Stock Market Move | NVIDIA Corporation holds Concept Stock Coreweave (CRWV.US), which fell more than 7%.
US Stock Market Move | Reach a $1.085 billion cooperation agreement with domestic and foreign pharmaceutical companies, Rani Therapeutics (RANI.US) soars over 265%.
RECOMMEND
